BIIB 最新10-Q变化
将 BIIB 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-10-28 与上一份 10-Q · 2026-07-29
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +73 | −65 | ~112 | 131 |
| 市场风险(第3项) | 文字有新增/删除 | +1 | 0 | ~5 | 7 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 5 |
| 风险因素 | 文字有新增/删除 | +13 | −12 | ~26 | 150 |
| 其他信息 | 文字有新增/删除 | +1 | −2 | ~1 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):法律诉讼
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-10-28
Drug prices are under significant scrutiny in many of the markets in which our products are prescribed. For example, legislation like the IRA has certain provisions related to drug pricing, including the ability for the U.S. government to exert considerable influence over prices for certain drugs in…
Additionally, in May 2025 the U.S. government issued an executive order aiming to establish an MFN drug pricing policy that would tie U.S. drug prices to the prices paid for drugs in other developed countries. HHS actions to set MFN pricing targets for prescription drugs, including the use of intern…
In September 2026, CMS published a final rule establishing the Global Benchmark for Efficient Drug Pricing Model, a mandatory Medicare Part B drug payment model that implements the current administration’s MFN pricing policy for drugs reimbursed under that program. The final rule is narrower than th…
These items and any additional legislation, regulations or initiatives related to drug pricing, such as the additional CMS-proposed MFN initiative, the Guarding U.S. Medicare Against Rising Drug Costs for certain Medicare Part D drugs, could create additional uncertainty around the timing and priori…
We continue to evaluate the potential impact of the actions discussed above on our business and operations.
相对上期删除的文字 · 来源:10-Q · 2026-07-29
Drug prices are under significant scrutiny in the markets in which our products are prescribed; for example the IRA has certain provisions related to drug pricing, including the ability for the U.S. government to set prices for certain drugs in Medicare. We expect drug pricing and other healthcare c…
Additionally, in May 2025 the U.S. government issued an executive order aiming to establish an MFN drug pricing policy that would tie U.S. drug prices to the prices paid for drugs in other developed countries. If HHS sets MFN pricing targets for prescription drugs, including the use of international…
On July 4, 2025, the U.S. signed into law the H.R.1 legislation formally titled "An Act to Provide for Reconciliation Pursuant to Title II of H. Con. Res. 14", commonly referred to as the OBBBA.
The OBBBA contains tax provisions, such as the permanent extension or revision of certain expiring provisions of the Tax Cuts and Jobs Act enacted in 2017, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The provisions …
Given the complexity of tax laws, related regulations and interpretations, our current estimates may require revision as additional information becomes available regarding the application of the OBBBA provisions.
市场风险(第3项)
相对上期新增的文字 · 来源:10-Q · 2026-10-28
by the value of non-U.S. expense, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue and expense will increase when reported in U.S. dollars.
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-10-28
experience with the development of such therapies. For example, we recently sought, and in July 2026 the FDA approved, of a subcutaneous formulation of LEQEMBI as a starting dose in the U.S. Our ability to realize the anticipated benefits from the subcutaneous formulation of LEQEMBI depends on among…
We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on…
Cybersecurity threats and incidents also include supply chain attacks, which could cause a delay in the manufacturing of products including products produced for contract manufacturing or lead to a data privacy or security breach. Our key business partners face similar risks and any security breach …
adversely affect our security posture. The integration of acquired businesses and their systems may also increase these risks. In addition, our increased use of cloud technologies heightens these and other operational risks, and any failure by cloud or other technology service providers to adequatel…
While we continue to build and improve our systems and infrastructure, including our business continuity and disaster recovery capabilities, there can be no assurance that our efforts will detect and prevent cybersecurity threats or incidents in our systems or that we will be able to restore affecte…
相对上期删除的文字 · 来源:10-Q · 2026-07-29
experience with the development of such therapies. For example, we are currently seeking approval of a subcutaneous formulation of LEQEMBI as a starting dose in the U.S. and any delays or challenges may impact our ability to realize the anticipated benefits from LEQEMBI.
We have made, and may continue to make, significant operating and capital expenditures for potential new products prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations.
We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on
similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies heightens these and other operational risks, and any failure by cloud or other technology service providers to adequately safeguard their systems a…
While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will detect and prevent cybersecurity threats or incidents in our systems and any such incidents could materially adversely affect our business a…
其他信息
相对上期新增的文字 · 来源:10-Q · 2026-10-28
In our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, we reported that on May 4, 2026, Lloyd Minor, a member of our Board of Directors, adopted a Rule 10b5-1 trading arrangement providing for the sale of up to 593 shares of our common stock. The correct aggregate number …
相对上期删除的文字 · 来源:10-Q · 2026-07-29
10b5-1Non-Rule 10b5-1Total Shares to be Purchased or SoldExpiration Date
(1) Dr. Singhal's Rule 10b5-1 trading arrangement provides for the sale of (i) up to 20,400 shares of our common stock and (ii) all of the shares of our common stock to be acquired under our Employee Stock Purchase Plan during the term of the 10b5-1 trading arrangement. The number of shares to be ac…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议